Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

NCT03538028 is registered in ClinicalTrials.gov with Incyte Biosciences International Sàrl as lead sponsor.

NCT NCT03538028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03538028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies
Lead sponsor
Incyte Biosciences International Sàrl
Phase
Phase 1
Overall status
Completed
Start date
June 18, 2018
Completion date
October 7, 2020
Enrollment
22 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, diffuse large b-cell lymphoma, esophageal cancer, gastric cancer (including stomach and gastroesophageal junction [gej]), hepatocellular carcinoma, melanoma (uveal melanoma excluded), merkel cell carcinoma, mesothelioma, microsatellite instability (msi)-high endometrial cancer, msi-high colorectal cancer, non-small cell lung cancer (nsclc), ovarian cancer, renal cell carcinoma (rcc), small cell lung cancer (sclc), squamous cell carcinoma of the head and neck (scchn), triple-negative breast cancer, urothelial carcinoma